Gal-3 induces anergy of CD8 T cells by distancing the T cell receptor (TCR) from the CD8 molecule, and impairs NK cell activity by inhibiting the interaction of the activating receptor natural-killer group 2, member D (NKG2D) expressed on NK cells and the heavily O-glycosylated tumor-derived MHC class I chain-related protein (MIC) A (15, 20, 21). The gene discussed is KLRK1; the disease is neoplasm.